Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Dcri-2400 Pratt Street, Room 0311-BOX 3850, Durham, NC 27710
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Chan, Austin W., William E. Bryan, Mohamed A. Hashem, Mary L. Townsend, Laura Ann Wang, Steve S. Choi, and Susanna Naggie. “Hepatitis C (HCV) Virologic Outcomes in Veterans taking Ledipasvir/Sofosbuvir with Concomitant Acid Suppressing Medication.” In Hepatology, 64:468A-468A. WILEY, 2016.

Scholars@Duke

Chan, Austin W., William E. Bryan, Mohamed A. Hashem, Mary L. Townsend, Laura Ann Wang, Steve S. Choi, and Susanna Naggie. “Hepatitis C (HCV) Virologic Outcomes in Veterans taking Ledipasvir/Sofosbuvir with Concomitant Acid Suppressing Medication.” In Hepatology, 64:468A-468A. WILEY, 2016.

Scholars@Duke

Asselah, Tarik, Gamal Shiha, Jordan J. Feld, Armando Abergel, Anita Kohli, Shyam Kottilil, Peter J. Ruane, et al. “Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection.” In Hepatology, 64:40A-41A. WILEY, 2016.

Scholars@Duke

Asselah, Tarik, Gamal Shiha, Jordan J. Feld, Armando Abergel, Anita Kohli, Shyam Kottilil, Peter J. Ruane, et al. “Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection.” In Hepatology, 64:40A-41A. WILEY, 2016.

Scholars@Duke

Naggie, Susanna, Eric Rosenthal, Sarah Kattakuzhy, Justin McGinnis, Sarjita Naik, Macky Natha, Joseph Llewellyn, et al. “Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts.” In Hepatology, 64:445A-445A. WILEY, 2016.

Scholars@Duke

Naggie, Susanna, Eric Rosenthal, Sarah Kattakuzhy, Justin McGinnis, Sarjita Naik, Macky Natha, Joseph Llewellyn, et al. “Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts.” In Hepatology, 64:445A-445A. WILEY, 2016.

Scholars@Duke

Sulkowski, Mark S., Curtis Cooper, Jean-Michel Molina, Susanna Naggie, K. C. Huang, Anu O. Osinusi, Luisa M. Stamm, et al. “High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials..” In Hepatology, 64:482A-483A. WILEY, 2016.

Scholars@Duke

Sulkowski, Mark S., Curtis Cooper, Jean-Michel Molina, Susanna Naggie, K. C. Huang, Anu O. Osinusi, Luisa M. Stamm, et al. “High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials..” In Hepatology, 64:482A-483A. WILEY, 2016.

Scholars@Duke

Fuchs, Michael, Timothy R. Morgan, Mariem Charafeddine, Norbert Brau, Warren N. Schmidt, Michael Kozal, Susanna Naggie, et al. “An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.” In Hepatology, 64:488A-488A. WILEY, 2016.

Scholars@Duke

Fuchs, Michael, Timothy R. Morgan, Mariem Charafeddine, Norbert Brau, Warren N. Schmidt, Michael Kozal, Susanna Naggie, et al. “An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.” In Hepatology, 64:488A-488A. WILEY, 2016.

Scholars@Duke

Pages